Medi-Exametazime (\(^{99m}\)Tc-HM-PAO)

**Active substance**
- Exametazime 500 µg

**Indications**
- Diagnostic study of *cerebrovascular disease* (acute stroke, chronic ischemia, transient ischemic attack):
  - presurgical laterization and localization of epileptogenic foci
  - dementia (Alzheimer's disease and frontotemporal dementia)
  - migraine
  - adjuvant technique in the diagnosis of brain death
- Labelled leucocyte scintigraphy:
  - *infectious or inflammatory diseases*:
    - localization of abnormal foci guiding the aetologic diagnosis in case of fever of unknown origin
    - diagnosis of infection in case of suspected osteomyelitis (with or without implants) and suspected hip or knee prosthesis infection
    - detection of the extension of inflammation in case of inflammatory bowel disease
  (for detailed information see SmPC)

**Excipients**
- Stannous(II) chloride dihydrate
- Tetrasodium pyrophosphate decahydrate

**Dose for adults**
- Brain perfusion SPECT: 350-500 MBq
- Labelled leucocyte scintigraphy: 200 MBq
  (for detailed information see SmPC)

**Labelling activity**
- 0.37-2.2 GBq

**Labelling volume**
- 5 ml

**Storage of cold kit**
- 12 months from date of manufacturing, between 2-8°C protected from light

**Storage of labelled compound**
- 1 hr below 25°C protected from light

**Package size**
- 6 vials

**Registration numbers**
- Denmark: DK R 49482
- Germany: 86253.00.00
- Austria: 4-00051
- United Kingdom: PL40129/0001M
- Turkey: F03950
- Spain: 77468
- Italy: pending

**Marketing Authorization Holder**
- Radiopharmacy Laboratory Co., Ltd.
  2040 Budaörs, Gyár u. 2., Hungary